Skip to main content

Day: February 18, 2021

PDF Solutions® Reports Fourth Quarter and Full Year 2020 Results

Business HighlightsTotal full year 2020 revenues of $88.0 million, up 3% year-over-yearAnalytics revenue grew by 15% for full year 2020 year-over-yearAnalytics accounted for 65% of total 2020 full year revenuesGAAP Gross Margin of 58% for full year 2020Non-GAAP Gross Margin of 63% for full year 2020Operating activities generated $21.8 million in cash during the full year 2020Cash, cash equivalents and short-term investments of $145.3 million at the end of 2020Strategic partnership with Advantest Corporation during the third quarter of 2020, including issuance of $65.2 million in our common stock and a five-year Exensio cloud-based subscription agreement for a minimum of $50.0 millionCompleted acquisition of Cimetrix Incorporated, a leading global provider of equipment connectivity products for smart manufacturing, during the fourth quarter...

Continue reading

Sienna Senior Living Inc. Provides Operations Update and Reports 2020 Fourth Quarter and Year-End Financial Results

MARKHAM, Ontario, Feb. 18, 2021 (GLOBE NEWSWIRE) — Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today provided an update on its operations and announced its financial results for the three months and year ended December 31, 2020. The Consolidated Financial Statements and accompanying Management’s Discussion and Analysis (“MD&A”) are available on the Company’s website at www.siennaliving.ca and on SEDAR at www.sedar.com.“With many of our residents and team members now vaccinated, we have new protection and renewed hope amid the evolving challenges of the pandemic,” said Nitin Jain, President and Chief Executive Officer of Sienna. “As we look beyond the pandemic, our development plans are progressing and our focus remains steadfast on the important role we play in the lives of our 13,000 team members and 10,000...

Continue reading

Larimar Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference

BALA CYNWYD, Pa., Feb. 18, 2021 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar Therapeutics, will present and participate in virtual 1×1 investor meetings at the SVB Leerink 10th Annual Global Healthcare Conference taking place virtually from February 22-26, 2021. See below for more details.About Larimar TherapeuticsLarimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the U.S. as a potential treatment for Friedreich’s ataxia....

Continue reading

AVITA Medical to Present at Upcoming Investor Conferences

VALENCIA, Calif. and MELBOURNE, Australia, Feb. 18, 2021 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that its management will present at the following upcoming investor conferences:Cowen 41stAnnual Healthcare ConferencePresenting on Thursday, March 4, 2021 at 11:10 a.m. Pacific Time / 2:10 p.m. Eastern Time (Australian time: Friday, March 5, 2021 at 6:10 a.m.)Oppenheimer 31stAnnual Healthcare ConferencePresenting on Tuesday, March 16, 2021 at 12:50 p.m. Pacific Time / 3:50 p.m. Eastern Time (Australian time: Wednesday, March 17, 2021 at 7:50 a.m.)The live, audio-only webcasts of the presentations may be accessed by visiting...

Continue reading

Cambium Networks Reports Fourth Quarter and Full Year 2020 Financial Results

Record revenues of $82.8 million, increased 13% sequentially, up 29% year-over-yearGross margin of 51.0%, non-GAAP(1) gross margin of 51.2%Record net income of $10.5 million or $0.38 per diluted share, record non-GAAP(1) net income of $10.7 million or $0.38 per diluted shareRecord Adjusted EBITDA(1) of $13.9 million or 16.8% of revenuesNet cash provided by operating activities $15.1 millionROLLING MEADOWS, Ill., Feb. 18, 2021 (GLOBE NEWSWIRE) — Cambium Networks Corporation (“Cambium Networks”) (NASDAQ: CMBM), a leading provider of wireless networking infrastructure solutions, today announced financial results for the fourth quarter and full year 2020 ended December 31, 2020.Refer to Supplemental Financial Information accompanying this press release for a reconciliation of GAAP to non-GAAP numbers and for reconciliation of adjusted...

Continue reading

Honey Badger Silver Announces $3 Million Non-Brokered Private Placement With Significant Participation by Mr. Eric Sprott and Management

TORONTO, Feb. 18, 2021 (GLOBE NEWSWIRE) — Honey Badger Silver Inc. (TSX-V: TUF) (“Honey Badger Silver” or the “Company”) is pleased to announce a non-brokered private placement financing of up to 42.86 million units at $0.07 per unit (“Unit”) for gross proceeds of up to $3,000,000 (the “Offering”). Each Unit will consist of one common share of Honey Badger Silver and one half of one common share purchase warrant (each whole warrant, a “Warrant”). Each whole Warrant will entitle the holder to acquire one additional common share of Honey Badger Silver at an exercise price of $0.10 for a period of three years from the date of closing of the Offering.Mr. Eric Sprott has confirmed his intention to subscribe for 14.29 million Units in the Offering for total gross proceeds to the Company of $1,000,000. This would...

Continue reading

Adverum Appoints Christopher J. DeRespino as Chief Business Officer

REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Christopher J. DeRespino as chief business officer, effective immediately. In this newly created position, Mr. DeRespino will lead corporate strategy and global business development efforts reporting to Laurent Fischer, M.D., Adverum’s chief executive officer.“Over the course of his career, which spans more than 15 years in the pharmaceutical industry, Chris has demonstrated an ability to drive business growth and value at leading companies in our sector,” said Laurent Fischer, M.D., chief executive officer at Adverum Biotechnologies. “Chris is joining our organization at an important time and we are...

Continue reading

Spark Power Announces $20 Million Bought Deal Public Offering of Convertible Debentures

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESOAKVILLE, Ontario, Feb. 18, 2021 (GLOBE NEWSWIRE) — Spark Power Group Inc. (“Spark Power” or the “Company”) (TSX: SPG) is pleased to announce that it has entered into a $20 million bought-deal financing (the “Convertible Debenture Financing”) of convertible unsecured subordinated debentures (the “Debentures”) with a syndicate of underwriters (the “Underwriters”) led by Raymond James Ltd. The Debentures will have a coupon of 7.5% per annum, and a conversion price of $3.05 per Spark Power common share (a “Common Share”), subject to adjustment in certain circumstances. The conversion price represents a conversion premium of approximately 25%. The Company has granted...

Continue reading

EURO Ressources reports earnings for the year ended December 31, 2020

EURO RESSOURCES REPORTS EARNINGS FOR THE YEAR ENDED DECEMBER 31, 2020Paris, France, February 18, 2021:  EURO Ressources S.A. (“EURO” or “the Company”) (Paris: EUR) today announced its audited statutory financial results prepared in accordance with French Generally Accepted Accounting Principles (“GAAP”) and its audited financial results prepared in accordance with International Financial Reporting Standards (“IFRS”) for the year ended December 31, 2020.  These audited financial results were approved by the Board of Directors on February 18, 2021.  All financial amounts are expressed in Euros (“€” or “euros”) unless otherwise specified.HighlightsUnder French GAAP, EURO reported a net profit of €10.8 million (€0.173 per share) for the year ended December 31, 2020, compared to €16.2 million (€0.259 per share) for the year ended December...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.